We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-10.3%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.69B
AUM Growth
-$784M
Cap. Flow
-$69.3M
Cap. Flow %
-1.88%
Top 10 Hldgs %
43.31%
Holding
160
New
14
Increased
20
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$37.8M
2
KYMR icon
Kymera Therapeutics
KYMR
+$34.9M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$31.1M
4
EVO icon
Evotec
EVO
+$26.8M
5
BLU
BELLUS Health Inc.
BLU
+$21.6M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$172M
2
ARGX icon
argenx
ARGX
+$23.5M
3
ITOS
iTeos Therapeutics
ITOS
+$15M
4
BABA icon
Alibaba
BABA
+$14.8M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.56%
2 Consumer Discretionary 6.51%
3 Financials 0.7%
4 Materials 0.48%
5 Consumer Staples 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LXRX icon
1
Lexicon Pharmaceuticals
LXRX
$1.03B
$280M 7.61%
71,178,364
– –
WW
2
DELISTED
WW International
WW
$239M 6.49%
14,818,300
– –
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$205M 5.57%
1,400,000
+200,000
+17% +$31.1M
ONC
4
BeOne Medicines Ltd
ONC
$34B
$183M 4.96%
675,000
+25,000
+4% +$8.44M
ARGX icon
5
argenx
ARGX
$55.2B
$175M 4.75%
500,000
-77,308
-13% -$23.5M
XBI icon
6
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
$112M 3.04%
+1,000,000
New +$121M
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$38.3B
$110M 2.99%
650,000
-50,000
-7% -$9.29M
SEER icon
8
Seer Inc
SEER
$114M
$108M 2.94%
4,750,000
– –
FATE icon
9
Fate Therapeutics
FATE
$276M
$105M 2.86%
1,800,000
+350,000
+24% +$19.8M
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
$77.3M 2.1%
500,000
+125,000
+33% +$20.9M
MORF
11
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$75.1M 2.04%
1,585,049
– –
FOLD
12
DELISTED
Amicus Therapeutics
FOLD
$69.3M 1.88%
6,000,000
-696,955
-10% -$7.77M
BLU
13
DELISTED
BELLUS Health Inc.
BLU
$68.4M 1.86%
8,500,000
+3,250,000
+62% +$21.6M
KYMR icon
14
Kymera Therapeutics
KYMR
$8.66B
$63.5M 1.72%
1,000,000
+600,000
+150% +$34.9M
BMY icon
15
CALL
Bristol-Myers Squibb
BMY
$129B
$62.4M 1.69%
1,000,000
– –
SRRK icon
16
Scholar Rock
SRRK
$5.88B
$60.9M 1.65%
2,450,000
+500,000
+26% +$13.8M
C icon
17
CALL
Citigroup
C
$213B
$60.4M 1.64%
1,000,000
-1,000,000
-50% -$66.5M
SWTX
18
DELISTED
SpringWorks Therapeutics
SWTX
$52.7M 1.43%
850,000
+250,000
+42% +$16.5M
ERAS icon
19
Erasca
ERAS
$6.15B
$49.4M 1.34%
3,172,221
– –
KRYS icon
20
Krystal Biotech
KRYS
$10.7B
$49M 1.33%
700,000
+200,000
+40% +$11.6M
CERE
21
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$48.6M 1.32%
1,500,000
-300,000
-17% -$10.6M
CYTK icon
22
Cytokinetics
CYTK
$10.6B
$45.6M 1.24%
1,000,000
-300,000
-23% -$11.6M
IGMS
23
DELISTED
IGM Biosciences
IGMS
$44M 1.19%
1,500,000
+150,000
+11% +$7.45M
PTGX icon
24
Protagonist Therapeutics
PTGX
$8.54B
$42.8M 1.16%
1,250,000
-250,000
-17% -$7.9M
SAGE
25
DELISTED
Sage Therapeutics
SAGE
$42.5M 1.15%
1,000,000
– –
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2021 Portfolio in Review

As of Q4 2021, Artal Group held 160 positions worth $3.69B, down 18% from $4.47B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group's Q4 2021 filing shows 14 new, 20 increased, 11 reduced and 10 closed positions. Its largest new stake was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M. The largest sale was Acceleron Pharma, an estimated $172M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 82% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q4 2021 buy was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M.
  • Artal Group added most to Kymera Therapeutics in Q4 2021, an estimated $34.9M increase.
  • Artal Group's biggest Q4 2021 reduction was argenx, cutting an estimated $23.5M.
  • Artal Group fully exited Acceleron Pharma in Q4 2021, selling an estimated $172M.
  • Artal Group's ten largest holdings make up 43% of its $3.69B portfolio in Q4 2021.
  • Artal Group opened 14 new positions and closed 10 in Q4 2021.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.69B.

Based on Artal Group's 13F filing for Q4 2021, filed 11 Feb 2022.